Unraveling Viral Interleukin-6 Binding to gp130 and Activation of STAT-Signaling Pathways Independently of the Interleukin-6 Receptor

被引:49
作者
Adam, Nina [1 ]
Rabe, Bjoern [1 ]
Suthaus, Jan [1 ]
Groetzinger, Joachim [1 ]
Rose-John, Stefan [1 ]
Scheller, Juergen [1 ]
机构
[1] Univ Kiel, Dept Biochem, Inst Biochem, D-24098 Kiel, Germany
关键词
SOLUBLE IL-6 RECEPTOR; DOUBLE TRANSGENIC MICE; EMBRYONIC STEM-CELLS; KAPOSIS-SARCOMA; DNA-SEQUENCES; HERPES-VIRUS; CYTOKINES; HOMOLOG; HUMAN-HERPESVIRUS-8; EXPRESSION;
D O I
10.1128/JVI.01601-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human herpesvirus 8 encodes a viral version of interleukin-6 (vIL-6) which shows 25% sequence homology with human IL-6. In contrast to human IL-6, which first binds to the IL-6 receptor (IL-6R) and only subsequently associates with the signal transducing receptor subunit gp130, vIL-6 has been shown to directly bind to gp130 without the need of IL-6R. As a functional consequence, vIL-6 can activate far more target cells in the body since all cells express gp130, but only cells such as hepatocytes and some leukocytes express IL-6R. We sought to understand which amino acid sequences within the vIL-6 protein were responsible for its ability to bind and activate gp130 independent of IL-6R. As a first approach, we constructed chimeric IL-6 proteins in which all known gp130 interacting sites (sites II and III) were sequentially transferred from vIL-6 into the human IL-6 protein. To our surprise, human IL-6 carrying all gp130 interacting sites from vIL-6 did not show IL-6R-independent gp130 activation. Even more surprisingly, the loop between helix B and C of vIL-6, clearly shown in the crystal structure not to be in contact with gp130, is indispensable for direct binding to and activation of gp130. This points to an IL-6R induced change of site III conformation in human IL-6, which is already preformed in vIL-6. These data indicate a novel activation mechanism of human IL-6 by the IL-6R that will be important for the construction of novel hyperactive cytokine variants.
引用
收藏
页码:5117 / 5126
页数:10
相关论文
共 49 条
[11]  
EHLERS M, 1994, J IMMUNOL, V153, P1744
[12]   A bioactive designer cytokine for human hematopoietic progenitor cell expansion [J].
Fischer, M ;
Goldschmitt, J ;
Peschel, C ;
Brakenhoff, JPG ;
Kallen, KJ ;
Wollmer, A ;
Grotzinger, J ;
RoseJohn, S .
NATURE BIOTECHNOLOGY, 1997, 15 (02) :142-145
[13]   IL-6 type cytokine receptor complexes:: Hexamer, tetramer or both? [J].
Grötzinger, J ;
Kernebeck, T ;
Kallen, KJ ;
Rose-John, S .
BIOLOGICAL CHEMISTRY, 1999, 380 (7-8) :803-813
[14]   MOLECULAR-CLONING AND EXPRESSION OF AN IL-6 SIGNAL TRANSDUCER, GP130 [J].
HIBI, M ;
MURAKAMI, M ;
SAITO, M ;
HIRANO, T ;
TAGA, T ;
KISHIMOTO, T .
CELL, 1990, 63 (06) :1149-1157
[15]   Human herpes virus 8 interleukin-6 homologue triggers gp130 on neuronal and hematopoietic cells [J].
Hoischen, SH ;
Vollmer, P ;
März, P ;
Özbek, S ;
Götze, KS ;
Peschel, C ;
Jostock, T ;
Geib, T ;
Müllerg, J ;
Mechtersheimer, S ;
Fisher, M ;
Grötzinger, J ;
Galle, PR ;
Rose-John, S .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2000, 267 (12) :3604-3612
[16]  
HONDA M, 1992, J IMMUNOL, V148, P2175
[17]   Maintenance of pluripotency in human embryonic stem cells is STAT3 independent [J].
Humphrey, RK ;
Beattie, GM ;
Lopez, AD ;
Bucay, N ;
King, CC ;
Firpo, MT ;
Rose-John, S ;
Hayek, A .
STEM CELLS, 2004, 22 (04) :522-530
[18]   Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses [J].
Jostock, T ;
Müllberg, J ;
Özbek, S ;
Atreya, R ;
Blinn, G ;
Voltz, N ;
Fischer, M ;
Neurath, MF ;
Rose-John, S .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 2001, 268 (01) :160-167
[19]   Receptor recognition sites of cytokines are organized as exchangeable modules -: Transfer of the leukemia inhibitory factor receptor-binding site from ciliary neurotrophic factor to interleukin-6 [J].
Kallen, KJ ;
Grötzinger, J ;
Lelièvre, E ;
Vollmer, P ;
Aasland, D ;
Renné, C ;
Müllberg, J ;
zum Buschenfelde, KHM ;
Gascan, H ;
Rose-John, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (17) :11859-11867
[20]  
Klouche M, 1999, J IMMUNOL, V163, P4583